We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Aliskiren, a direct renin inhibitor, in clinical practice: a new approach in the treatment of hypertension.
- Authors
Moutzouri, E; Florentin, M; Elisaf, M S; Mikhailidis, D P; Liberopoulos, E N
- Abstract
Arterial hypertension is an important risk factor for the development and progression of cardiovascular disease (CVD). The renin angiotensin aldosterone system (RAAS) plays a crucial role in the pathophysiology of hypertension and associated complications. Direct renin inhibitors (DRIs) are novel antihypertensive drugs which inhibit the first step of RAAS. Aliskiren is the first orally active DRI approved as monotherapy or in combination with other antihypertensive agents for the treatment of hypertension.
- Publication
Current vascular pharmacology, 2010, Vol 8, Issue 3, p344
- ISSN
1875-6212
- Publication type
Journal Article
- DOI
10.2174/157016110791112322